Quick reference guide to apixaban [Corrigendum]
Authors Hurst KV, O'Callaghan JM, Handa A
Received 26 September 2017
Accepted for publication 26 September 2017
Published 26 October 2017 Volume 2017:13 Pages 413—414
Hurst KV, O’Callaghan JM, Handa A. Vascular Health and Risk Management. 2017:13 263–267.
On page 264, Table 2 states that the apixaban dose should be reduced in patients with mild hepatic impairment and that it is not indicated in patients with moderate-to-severe hepatic impairment. This is also stated in the text to the left of that table.
The authors amend this to:
Apixaban dose adjustment is not required in patients with mild or moderate hepatic impairment, however it should be used with caution in these patients and dose adjustment may be needed. Apixaban is not recommended in patients with severe hepatic impairment.
Read the original article
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]